Coronary Artery Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Coronary Artery Disease Pipeline Insight 2024" report provides comprehensive insights about 30+ Coronary Artery Disease companies and 25+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. Coronary Artery Disease pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Coronary Artery Disease Research. Learn more about our innovative pipeline today! @ Coronary Artery Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Coronary Artery Disease Pipeline Report

* In October 2024:- Novarits Pharmaceuticals- The purpose of this study is to evaluate the efficacy of inclisiran compared to placebo on top of maximally tolerated dose of statin therapy in reducing total coronary atheroma volume assessed by CCTA in participants with a diagnosis of Non-Obstructive Coronary Artery Disease (NOCAD) without previous cardiovascular events, who have an LDL-C greater than or equal to 55 mg/dL (1.4 mmol//L), no significant pressure drop in Fractional Flow Reserve Computed Tomography (FFRCT) and a CT-adapted Leaman score >5 despite the use of maximally tolerated statin therapy(and if applicable, another LLT on top of statin therapy for at least 30 days in up to 20% of randomized participants).
* In October 2024:- CSL Behring- This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double blind, placebo controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on CV outcomes and safety in subjects with ASCVD or diabetes mellitus and evidence of systemic inflammation who are undergoing maintenance dialysis.
* In October 2024:- DalCor Pharmaceuticals- This is an event-driven study and will last until approximately 200 subjects have experienced a primary event, unless the study is stopped at the planned interim analysis. Visits after randomization will be performed as virtual visits where permissible every 3 months or as clinic visits until the study is stopped. For any subject prematurely discontinuing study medication, assessments will be conducted every 3 months for the collection of study endpoints.
* DelveInsight's Coronary Artery Disease pipeline report depicts a robust space with 30+ active players working to develop 25+ pipeline therapies for Coronary Artery Disease treatment.
* The leading Coronary Artery Disease Companies such as Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences , and others.
* Promising Coronary Artery Disease Therapies such as Inclisiran sodium 300 mg, Lansoprazole 15 mg, DFV890, Evolocumab, Regadenoson, Sarpogrelate Sustained Release/Aspirin, Tirzepatide , and others.

Stay informed about the cutting-edge advancements in Coronary Artery Disease Treatments. Download for updates and be a part of the revolution in cancer care @ Coronary Artery Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Coronary Artery Disease Emerging Drugs

* Flurpiridaz F-18: GE Healthcare

Flurpiridaz F-18, a fluorine 18-labeled agent was developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease (CAD), the most common form of heart disease. Flurpiridaz F 18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent. GE Healthcare has launched a second Phase III clinical trial for the use of Flurpiridaz 18F Injection in PET myocardial perfusion imaging (MPI) to detect CAD. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

* Evolocumab: Amgen

Evolocumab injection is used to reduce the risk of a stroke or heart attack or the need for coronary artery bypass (CABG) surgery in people with cardiovascular disease. Evolocumab injection is also used along with diet alone or in combination with other cholesterol-lowering medications such as HMG-CoA reductase inhibitors (statins) or ezetimbe (Zetia) to decrease the amount of low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood, including people who have familial heterozygous hypercholesterolemia. It is also used along with diet changes and other treatments to reduce the amount low-density lipoprotein (LDL) cholesterol in the blood in people that have homozygous familial hypercholesterolemia. It is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibody. It works by blocking the production of LDL cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Currently, it is in Phase III stage of clinical trial evaluation to treat Coronary Artery Disease.

* Revacept: advanceCor

Revacept seals the lesion in a blood vessel like a plaster. It acts locally at the ruptured plaque instead of involving the complete organism, as is the case for all established drugs. Revacept has proven to be very effective in laboratory tests with platelets and in animal experiments. In a Phase I clinical trial with volunteers, it was shown to be very well tolerated at all dosages. It induced a specific and dose-dependent inhibition of aggregation (clumping of platelets) in the blood of the volunteers without any relevant side effects. In particular, general haemostasis was not affected: The bleeding time was not prolonged by Revacept and there were no bleeding complications and no reduction in platelet count (thrombopenia). Currently, it is in Phase II stage of clinical trial evaluation to treat Coronary Artery Disease.

Learn more about Coronary Artery Disease Drugs opportunities in our groundbreaking Coronary Artery Disease Research and development projects @ Coronary Artery Disease Unmet Needs [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Coronary Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.

Coronary Artery Disease Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Coronary Artery Disease Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Coronary Artery Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Coronary Artery Disease Pipeline Report

* Coverage- Global
* Coronary Artery Disease Companies- Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences, and others.
* Coronary Artery Disease Therapies- Inclisiran sodium 300 mg, Lansoprazole 15 mg, DFV890, Evolocumab, Regadenoson, Sarpogrelate Sustained Release/Aspirin, Tirzepatide, and others.
* Coronary Artery Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Coronary Artery Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Coronary Artery Disease Pipeline on our website @ Coronary Artery Disease Drugs and Companies [https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Coronary Artery Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Coronary Artery Disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Evolocumab: Amgen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ninerafaxstat: Imbria Pharmaceuticals, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Coronary Artery Disease Key Companies
* Coronary Artery Disease Key Products
* Coronary Artery Disease- Unmet Needs
* Coronary Artery Disease- Market Drivers and Barriers
* Coronary Artery Disease- Future Perspectives and Conclusion
* Coronary Artery Disease Analyst Views
* Coronary Artery Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=coronary-artery-disease-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.